Xencor Inc
NASDAQ:XNCR

Watchlist Manager
Xencor Inc Logo
Xencor Inc
NASDAQ:XNCR
Watchlist
Price: 24.57 USD 1.82% Market Closed
Market Cap: 1.7B USD
Have any thoughts about
Xencor Inc?
Write Note

Xencor Inc
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Xencor Inc
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Xencor Inc
NASDAQ:XNCR
Depreciation & Amortization
$12.3m
CAGR 3-Years
21%
CAGR 5-Years
25%
CAGR 10-Years
30%
Abbvie Inc
NYSE:ABBV
Depreciation & Amortization
$8.4B
CAGR 3-Years
-1%
CAGR 5-Years
34%
CAGR 10-Years
27%
Gilead Sciences Inc
NASDAQ:GILD
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Depreciation & Amortization
$5.6B
CAGR 3-Years
18%
CAGR 5-Years
23%
CAGR 10-Years
11%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Depreciation & Amortization
$219.7m
CAGR 3-Years
22%
CAGR 5-Years
17%
CAGR 10-Years
13%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Depreciation & Amortization
$469.5m
CAGR 3-Years
20%
CAGR 5-Years
19%
CAGR 10-Years
25%
No Stocks Found

Xencor Inc
Glance View

Market Cap
1.7B USD
Industry
Biotechnology

Xencor Inc. is an innovative biotechnology company, distinguished by its commitment to harnessing the power of engineered monoclonal antibodies to fight complex diseases, especially within the realms of cancer and autoimmune disorders. Founded in 1997 and headquartered in Monrovia, California, Xencor relies on its proprietary XmAb technology platform – a sophisticated approach that enhances the structure and function of monoclonal antibodies to improve therapeutic performance. This technology enables Xencor to develop antibodies that are more potent, stable, and precise, ultimately driving their efficacy in targeting particular cellular mechanisms associated with disease progression while minimizing side effects. By focusing on core biological processes, Xencor leverages its platform to innovate new therapies that offer significant improvements over existing treatments, making it a nimble player in the competitive biotech landscape. Xencor's business model hinges on a dual strategy of internal drug development and strategic collaborations. Internally, Xencor is advancing a robust pipeline of drug candidates aimed at addressing various unmet medical needs, many of which are in various stages of clinical trials. These in-house projects are crucial for establishing the company's reputation as a leader in antibody engineering. In parallel, Xencor partners with larger pharmaceutical companies, licensing its XmAb technology and co-developing drugs—a model that provides a steady revenue stream from milestone payments, royalties, and research support. This hybrid approach not only diversifies Xencor's risk portfolio but also enhances its financial resilience, enabling a sustainable path to growth amidst the volatile biotech sector. Through this innovative framework, Xencor is poised to continue its influence in the biopharmaceutical industry, driven by a mission to bring transformative therapies to patients in need.

XNCR Intrinsic Value
16.09 USD
Overvaluation 34%
Intrinsic Value
Price

See Also

What is Xencor Inc's Depreciation & Amortization?
Depreciation & Amortization
12.3m USD

Based on the financial report for Sep 30, 2024, Xencor Inc's Depreciation & Amortization amounts to 12.3m USD.

What is Xencor Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
30%

Over the last year, the Depreciation & Amortization growth was 17%. The average annual Depreciation & Amortization growth rates for Xencor Inc have been 21% over the past three years , 25% over the past five years , and 30% over the past ten years .

Back to Top